MEDIA
Latest News
Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.
Main Menu
- 21 April 2022
Revance Therapeutics (RVNC) Announces FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines)
- 21 April 2022
Revance Receives FDA Acceptance of BLA Resubmission for DaxiboutlinumtoxinA for Glabellar Lines
- 18 April 2022